Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment.

Curr Neuropharmacol · 2026 · PMC13269908 · PMID 40873276

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In patients with RMS, an incomplete B-cell depletion or higher B-cell counts in blood before the next infusion showed a trend toward elevated risk of disease progression [ 77 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.